Biotech venture capitalists are embracing risk again, signaling a reversal from the past few years.
VCs are placing more bets on flashy new biotech opportunities in the first quarter of 2026. About 65% of investments …
Welcome back to another edition of Endpoints Weekly. Two of the year’s major oncology conferences are coming up soon: AACR starting April 17, and ASCO
Following a judge’s ruling that suspended most of the Trump administration’s appointments to the CDC’s vaccine advisory panel, a newly published charter for the panel
The price differential between the US and other countries “will be significantly narrower or smaller” going forward because of pressure from the Trump administration’s “most
The FDA has once again rejected Replimune’s oncolytic virus therapy to treat advanced melanoma. The Massachusetts-based drugmaker had been pushing for a reconsideration by the
Five people with beta thalassemia who had their blood stem cells genetically altered no longer require regular blood transfusions to stay healthy. Their Chinese-made treatment
Biotech venture capitalists are embracing risk again, signaling a reversal from the past few years.
VCs are placing more bets on flashy new biotech opportunities in the first quarter of 2026. About 65% of investments …